Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.
Clinical trials
Immunomodulatory drugs+
Sex differences
myeloma
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
30
11
2020
accepted:
16
04
2021
pubmed:
2
6
2021
medline:
9
2
2022
entrez:
1
6
2021
Statut:
ppublish
Résumé
Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored. We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated. Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were more likely to meet the cytogenetic classification of high-risk (HiR) or ultra-high-risk disease (UHiR). There was no difference in progression-free survival (PFS) or overall survival (OS) between the sexes in the overall population. Our data suggest that the genetic lesions involved in the initiation and progression of MM may be different between the sexes. Although females were more likely to have the poor prognosis lesions t(14;16) and del(17p), and were more likely to be assessed as having HiR or UHiR disease, this was not associated with reduced PFS or OS. In female patients the trial treatment may have been able to overcome some of the adverse effects of high-risk cytogenetic lesions. MicroAbstract Multiple myeloma (MM) is more common in males compared to females but the reasons behind this are not well understood and the impact of sex on patient outcomes is unclear. This study demonstrates fundamental differences in genetic lesions underlying the biology of MM between males and females. However, we found that progression-free survival and overall survival were the same in both sexes.
Sections du résumé
BACKGROUND
Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored.
PATIENTS AND METHODS
We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated.
RESULTS
Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were more likely to meet the cytogenetic classification of high-risk (HiR) or ultra-high-risk disease (UHiR). There was no difference in progression-free survival (PFS) or overall survival (OS) between the sexes in the overall population.
CONCLUSION
Our data suggest that the genetic lesions involved in the initiation and progression of MM may be different between the sexes. Although females were more likely to have the poor prognosis lesions t(14;16) and del(17p), and were more likely to be assessed as having HiR or UHiR disease, this was not associated with reduced PFS or OS. In female patients the trial treatment may have been able to overcome some of the adverse effects of high-risk cytogenetic lesions. MicroAbstract Multiple myeloma (MM) is more common in males compared to females but the reasons behind this are not well understood and the impact of sex on patient outcomes is unclear. This study demonstrates fundamental differences in genetic lesions underlying the biology of MM between males and females. However, we found that progression-free survival and overall survival were the same in both sexes.
Identifiants
pubmed: 34059488
pii: S2152-2650(21)00157-9
doi: 10.1016/j.clml.2021.04.013
pmc: PMC8528179
pii:
doi:
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
667-675Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Br J Haematol. 2002 Sep;118(4):1071-7
pubmed: 12199787
Expert Rev Hematol. 2012 Dec;5(6):603-17
pubmed: 23216592
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342
pubmed: 29949843
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1703-7
pubmed: 21680536
Clin Cancer Res. 2013 Nov 1;19(21):6030-8
pubmed: 23995858
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Pflugers Arch. 2007 Dec;455(3):397-429
pubmed: 17638010
Br J Haematol. 1977 Oct;37(2):295-300
pubmed: 603762
Biomed J. 2014 Sep-Oct;37(5):269-83
pubmed: 25163501
Hematol Rep. 2013 Feb 11;5(1):13-7
pubmed: 23888240
Blood Cancer J. 2018 Jul 6;8(7):67
pubmed: 29980678
Blood Rev. 2014 Mar;28(2):41-7
pubmed: 24491804
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Adv Immunol. 2014;122:1-57
pubmed: 24507154
Cancer Epidemiol. 2015 Dec;39(6):892-900
pubmed: 26520618
Br J Haematol. 2021 Feb;192(3):e66-e69
pubmed: 33216365
Eur J Public Health. 2011 Jun;21(3):387-91
pubmed: 20650944
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1629-37
pubmed: 21750167
Oncology. 2017;93(5):295-301
pubmed: 28803241